Drug intelligence / Profile preview

GSK2256098 + trametinib

Development stage: Unknown
Lead developer: GSK
Modality: Small Molecules
Administration: Oral

Overview

GSK2256098 + trametinib is a combination therapy consisting of GSK2256098, an oral focal adhesion kinase (FAK) inhibitor, and trametinib, an oral allosteric MEK1/2 inhibitor. The combination targets two frequently co-activated pathways in cancer: FAK signaling, which plays a role in cancer cell growth and spread, and the MAPK pathway, which is often activated by KRAS mutations. This combination has been studied in advanced solid tumors, particularly pancreatic ductal adenocarcinoma (PDAC) and mesothelioma.

Targets

MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)FAK (Focal adhesion kinase)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)

Beyond the preview

Go deeper on GSK2256098 + trametinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSK2256098 + trametinib.

Explore the full profile